{"id":464664,"date":"2021-03-24T17:18:20","date_gmt":"2021-03-24T21:18:20","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=464664"},"modified":"2021-03-24T17:18:20","modified_gmt":"2021-03-24T21:18:20","slug":"bioasis-technologies-inc-confirms-tsxv-approval-of-warrant-extension-and-repricing","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/bioasis-technologies-inc-confirms-tsxv-approval-of-warrant-extension-and-repricing\/","title":{"rendered":"Bioasis Technologies Inc. Confirms TSXV Approval of Warrant Extension and Repricing"},"content":{"rendered":"<div class=\"mw_release\">\n<p>NEW HAVEN, Conn., March  24, 2021  (GLOBE NEWSWIRE) &#8212;  <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=puXjlIb-NQPDOuchr0E5nFYfOjYYEFrmf2NBpHEdY7iY6Xz74IlZbXFZm2prV6EI_dmKWfG5GbzCsdPjiD38Tw9u-1FQzWDD7ldf19tKLog=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>BIOASIS TECHNOLOGIES INC.<\/u><\/a>\u00a0(TSX.V:BTI; OTCQB:BIOAF;), (\u201c<strong>Bioasis<\/strong>\u201d or the \u201c<strong>Company<\/strong>\u201d), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB<sup>3 <\/sup>\u2122\u00a0platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, is pleased to confirm that it has received approval from the TSX Venture Exchange for the previously announced amendments to the terms of 5,797,795 common share purchase warrants issued to subscribers pursuant to the private placement of units which closed on April 11, 2017. The expiry date of the warrants has been extended from April 11, 2021 until April 11, 2022 and exercise price has been reduced from $1.00 to $0.85.<\/p>\n<p>All other terms of the warrants remain unchanged for the extended exercise period.<\/p>\n<p>\n        <strong>Contacts<\/strong>\n      <\/p>\n<p>On behalf of the Board of Directors of Bioasis Technologies Inc.<\/p>\n<p>Deborah Rathjen<br \/>Executive Chair of the Board<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YCyQjWD1NYfpvDq1iaZqqx2UtWC5UEmUNPPh_9reVBGogQ56cIYPEKd2Qzal-wVsPk5V49DXNx1ZFoSscx-JxE7lzIrk9dl0F1xWJortASU=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">deborah@bioasis.us<\/a><br \/>+1 203 533 7082<\/p>\n<p>\n        <strong>Follow on<\/strong>\n      <\/p>\n<p>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=U5Esu7PE5FoPbBa65ViOhXj26CArv5fA5b1_W-nCU3LZ0YA0kYd6SQK0Bp-GLoP-Ok3vfLaKC9bAl4NIfYRYwF2hWVnu8MP6k1IyYWzV8us=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Facebook<\/a><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EG_vuRb_O-dTNVbxBGs5ylyMQOSgeDH2kAKvupPBZ6wWYPYBHCdihUJLLhYpyKj3ioU989XgeenT6unqvxZxxbHDa7KZjaJfPnUqbbST9eU=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Instagram<\/a><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mjQi-nNDFMDz3wTWX_ImQLLH_W4G8Mogsu4j-WZkg1iuuY_mQmuI8xXyFrl1tbeAjJbKctrOvtdZrN5uX7Bu_-9CWVwu4p8n_lJGNPG3XW8=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">LinkedIn<\/a><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Bl6OtqL-rDmoBIEmfH6Md_zRkNdggrQjJP4HmOwIiwSiP56Za4J1b-CC1wYrs8W8ek60vMsRS3BfRc4NiJ9VaA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Twitter<\/a>\n      <\/p>\n<p>BTI-CRP<\/p>\n<p>\n        <strong>About Bioasis<\/strong>\n      <\/p>\n<p>Bioasis Technologies Inc. is a biopharmaceutical company developing the xB<sup>3<\/sup> \u2122 platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The delivery of therapeutics across the blood brain barrier represents the final frontier in treating neurological disorders. The in-house development programs at Bioasis are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders. For more information about the Company, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xBLck8ccxXCdysYs16k03eG2JHl2KghwEVqbGyKNQfMxEgcC9I-h9jAF5r674Lr-B-uudT3_Lo1H-RAqtjl9sg==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.bioasis.us<\/a>.<\/p>\n<p>\n        <strong>Forward Looking Statements<\/strong><br \/>\n        <br \/>Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact along with other statements containing the words \u201cbelieve,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cwill,\u201d \u201cestimate,\u201d \u201ccontinue,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cexpect\u201d and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: products that we develop may not succeed in preclinical or clinical trials, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.<\/p>\n<p>Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwNjA0MiM0MDkwNjIwIzIxOTkzNTc=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/7374a9b4-a20f-49d0-b2d0-eb51ecde2703\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW HAVEN, Conn., March 24, 2021 (GLOBE NEWSWIRE) &#8212; BIOASIS TECHNOLOGIES INC.\u00a0(TSX.V:BTI; OTCQB:BIOAF;), (\u201cBioasis\u201d or the \u201cCompany\u201d), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 \u2122\u00a0platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, is pleased to confirm that it has received approval from the TSX Venture Exchange for the previously announced amendments to the terms of 5,797,795 common share purchase warrants issued to subscribers pursuant to the private placement of units which closed on April 11, 2017. The expiry date of the warrants has been extended from April 11, 2021 until April 11, 2022 and exercise &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bioasis-technologies-inc-confirms-tsxv-approval-of-warrant-extension-and-repricing\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Bioasis Technologies Inc. Confirms TSXV Approval of Warrant Extension and Repricing&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-464664","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Bioasis Technologies Inc. Confirms TSXV Approval of Warrant Extension and Repricing - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bioasis-technologies-inc-confirms-tsxv-approval-of-warrant-extension-and-repricing\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bioasis Technologies Inc. Confirms TSXV Approval of Warrant Extension and Repricing - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW HAVEN, Conn., March 24, 2021 (GLOBE NEWSWIRE) &#8212; BIOASIS TECHNOLOGIES INC.\u00a0(TSX.V:BTI; OTCQB:BIOAF;), (\u201cBioasis\u201d or the \u201cCompany\u201d), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 \u2122\u00a0platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, is pleased to confirm that it has received approval from the TSX Venture Exchange for the previously announced amendments to the terms of 5,797,795 common share purchase warrants issued to subscribers pursuant to the private placement of units which closed on April 11, 2017. The expiry date of the warrants has been extended from April 11, 2021 until April 11, 2022 and exercise &hellip; Continue reading &quot;Bioasis Technologies Inc. Confirms TSXV Approval of Warrant Extension and Repricing&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/bioasis-technologies-inc-confirms-tsxv-approval-of-warrant-extension-and-repricing\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-24T21:18:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwNjA0MiM0MDkwNjIwIzIxOTkzNTc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioasis-technologies-inc-confirms-tsxv-approval-of-warrant-extension-and-repricing\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioasis-technologies-inc-confirms-tsxv-approval-of-warrant-extension-and-repricing\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Bioasis Technologies Inc. Confirms TSXV Approval of Warrant Extension and Repricing\",\"datePublished\":\"2021-03-24T21:18:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioasis-technologies-inc-confirms-tsxv-approval-of-warrant-extension-and-repricing\\\/\"},\"wordCount\":695,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioasis-technologies-inc-confirms-tsxv-approval-of-warrant-extension-and-repricing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwNjA0MiM0MDkwNjIwIzIxOTkzNTc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioasis-technologies-inc-confirms-tsxv-approval-of-warrant-extension-and-repricing\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioasis-technologies-inc-confirms-tsxv-approval-of-warrant-extension-and-repricing\\\/\",\"name\":\"Bioasis Technologies Inc. Confirms TSXV Approval of Warrant Extension and Repricing - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioasis-technologies-inc-confirms-tsxv-approval-of-warrant-extension-and-repricing\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioasis-technologies-inc-confirms-tsxv-approval-of-warrant-extension-and-repricing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwNjA0MiM0MDkwNjIwIzIxOTkzNTc=\",\"datePublished\":\"2021-03-24T21:18:20+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioasis-technologies-inc-confirms-tsxv-approval-of-warrant-extension-and-repricing\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioasis-technologies-inc-confirms-tsxv-approval-of-warrant-extension-and-repricing\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioasis-technologies-inc-confirms-tsxv-approval-of-warrant-extension-and-repricing\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwNjA0MiM0MDkwNjIwIzIxOTkzNTc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwNjA0MiM0MDkwNjIwIzIxOTkzNTc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioasis-technologies-inc-confirms-tsxv-approval-of-warrant-extension-and-repricing\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bioasis Technologies Inc. Confirms TSXV Approval of Warrant Extension and Repricing\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Bioasis Technologies Inc. Confirms TSXV Approval of Warrant Extension and Repricing - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/bioasis-technologies-inc-confirms-tsxv-approval-of-warrant-extension-and-repricing\/","og_locale":"en_US","og_type":"article","og_title":"Bioasis Technologies Inc. Confirms TSXV Approval of Warrant Extension and Repricing - Market Newsdesk","og_description":"NEW HAVEN, Conn., March 24, 2021 (GLOBE NEWSWIRE) &#8212; BIOASIS TECHNOLOGIES INC.\u00a0(TSX.V:BTI; OTCQB:BIOAF;), (\u201cBioasis\u201d or the \u201cCompany\u201d), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 \u2122\u00a0platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, is pleased to confirm that it has received approval from the TSX Venture Exchange for the previously announced amendments to the terms of 5,797,795 common share purchase warrants issued to subscribers pursuant to the private placement of units which closed on April 11, 2017. The expiry date of the warrants has been extended from April 11, 2021 until April 11, 2022 and exercise &hellip; Continue reading \"Bioasis Technologies Inc. Confirms TSXV Approval of Warrant Extension and Repricing\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/bioasis-technologies-inc-confirms-tsxv-approval-of-warrant-extension-and-repricing\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-24T21:18:20+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwNjA0MiM0MDkwNjIwIzIxOTkzNTc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioasis-technologies-inc-confirms-tsxv-approval-of-warrant-extension-and-repricing\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioasis-technologies-inc-confirms-tsxv-approval-of-warrant-extension-and-repricing\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Bioasis Technologies Inc. Confirms TSXV Approval of Warrant Extension and Repricing","datePublished":"2021-03-24T21:18:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioasis-technologies-inc-confirms-tsxv-approval-of-warrant-extension-and-repricing\/"},"wordCount":695,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioasis-technologies-inc-confirms-tsxv-approval-of-warrant-extension-and-repricing\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwNjA0MiM0MDkwNjIwIzIxOTkzNTc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioasis-technologies-inc-confirms-tsxv-approval-of-warrant-extension-and-repricing\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/bioasis-technologies-inc-confirms-tsxv-approval-of-warrant-extension-and-repricing\/","name":"Bioasis Technologies Inc. Confirms TSXV Approval of Warrant Extension and Repricing - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioasis-technologies-inc-confirms-tsxv-approval-of-warrant-extension-and-repricing\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioasis-technologies-inc-confirms-tsxv-approval-of-warrant-extension-and-repricing\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwNjA0MiM0MDkwNjIwIzIxOTkzNTc=","datePublished":"2021-03-24T21:18:20+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioasis-technologies-inc-confirms-tsxv-approval-of-warrant-extension-and-repricing\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/bioasis-technologies-inc-confirms-tsxv-approval-of-warrant-extension-and-repricing\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioasis-technologies-inc-confirms-tsxv-approval-of-warrant-extension-and-repricing\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwNjA0MiM0MDkwNjIwIzIxOTkzNTc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwNjA0MiM0MDkwNjIwIzIxOTkzNTc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioasis-technologies-inc-confirms-tsxv-approval-of-warrant-extension-and-repricing\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Bioasis Technologies Inc. Confirms TSXV Approval of Warrant Extension and Repricing"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/464664","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=464664"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/464664\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=464664"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=464664"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=464664"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}